Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PRM-151

Known as: PRM-151/PTX2, Recombinant Human PTX2, Recombinant Human Serum Amyloid P/Pentraxin 2 
A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Homeodomain ProteinsRecombinant ProteinsSerum Amyloid P-Component

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
Introduction: PRM-151, a recombinant human pentraxin-2 molecule, has been shown to prevent and reverse fibrosis in animal models… Expand
Is this relevant?
2016
2016
Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.
Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2016
2016
Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.
Pentraxin-2 (PTX-2), also known as serum amyloid P component (SAP/APCS), is a constitutive, antiinflammatory, innate immune… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151
S58 63.4% intermediate-1 63.4%, intermediate-2 28.1% and none high risk. Anemia was the most frequent laboratorial finding (67… Expand
Is this relevant?
2014
2014
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results
PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue damage, inducing… Expand
Is this relevant?
2014
2014
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
7114 Background: PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue… Expand
Is this relevant?
2013
2013
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.
PRM-151, recombinant human Pentraxin-2 (PTX-2) also referred to as serum amyloid P (SAP), is under development for treatment of… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2013
2013
Characterization and stabilization of recombinant human protein pentraxin (rhPTX-2).
The potential human therapeutic protein pentraxin (PTX-2) is a large, glycosylated plasma protein consisting of five monomers… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2011
2011
Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits.
This study investigated whether PRM-151 (Promedior, Inc., Malvern, PA), a recombinant form of human pentraxin-2 (PTX-2, also… Expand
  • figure 1
Is this relevant?
2011
2011
Recombinant Human Pentraxin-2 (PRM-151): Leveraging Nature’s Mechanism of Fibrocyte and Monocyte Regulation to Treat Disease
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE